Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

MolDX covers MRD testing (notably ClonoSeq®) for specified hematologic malignancies (ALL, MM, CLL, DLBCL, MCL) and allows single-gene PCR MRD tests (e.g., BCR-ABL1) per guideline-driven schedules. Billing requires registration with DEX®, submission of the assigned DEX Z-Code adjacent to the CPT (use CPT 81479 for multi-analyte NGS panels), 1 UOS per episode or date of service as specified, with limits of no more than once per 30 days and generally one episode per diagnosis unless documented genetic change justifies additional testing.

"ClonoSeq® testing is covered for MRD assessment in acute lymphoblastic leukemia (ALL)."

Sign up to see full coverage criteria, indications, and limitations.